BMS-8

• CAT Number: R067118
• CAS Number: 1675201-90-7
• Molecular Formula: C27H28BrNO3
• Molecular Weight: 494.42
• Purity: ≥95%
• Synonyms: 1-[[3-bromo-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]piperidine-2-carboxylic acid
• InChI: InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)
• InChIKey: QRXBPPWUGITQLE-UHFFFAOYSA-N
• SMILES: CC1=C(C=CC=C1C2=CC=CC=C2)COC3=C(C=C(C=C3)CN4CCCCC4C(=O)O)Br

BMS-8(CAT: R067118) is a synthetic small molecule that acts as a selective agonist for the melatonin receptors MT1 and MT2. Developed by Bristol-Myers Squibb, BMS-8 is primarily used in research to study the role of melatonin in regulating circadian rhythms, sleep-wake cycles, and other physiological processes influenced by melatonin signaling. Unlike natural melatonin, BMS-8 has been designed to have enhanced potency and selectivity, making it a valuable tool in pharmacological studies aimed at understanding the therapeutic potential of melatonin receptor modulation. This compound has also been explored for its potential applications in treating sleep disorders, depression, and other conditions related to circadian rhythm disruption.